Therapeutic Results of Two Regimens for Childhood Acute Myelogenous Leukemia / 대한소아혈액종양학회지
Korean Journal of Pediatric Hematology-Oncology
;
: 68-77, 1999.
Artículo
en Coreano
| WPRIM
| ID: wpr-24338
ABSTRACT
PURPOSE:
The purpose of this study was to compare the therapeutic results between the two groups of children with acute myelogenous leukemia (AML) who were treated either by 3-year Okayama regimen or by 2-year KSBRM regimen.METHODS:
The subjects were 38 newly diagnosed AML patients at Chonnam University Hospital from Apr. 1991 to Dec. 1998. Until April, 1994, 10 patients were treated by the Okayama regimen for 3 years while 28 patients received KSBRM regimen for 2 years thereafter. The remission induction rate, relapse rate, and survival rate were compared retrospectively between the two groups.RESULTS:
1) The remission induction rate was 78.9% (30/38) Okayama group, 80.0% (8/10); KSBRM group, 78.6% (22/28). 2) The relapse rate after remission in the Okayama group was 37.5% (3/8) while that in the KSBRM group was 27.3% (6/22). 3) Deaths were encountered in 16 patients (42.1%) 60.0% (6/10) of Okayama group vs 35.7% (10/28) of KSBRM group (P=0.27). 4) Kaplan-Meier 3-year disease free survival (DFS) for all of the patients was 45.2%. The 3-year DFS was 40.0% for Okayama group and 48.2% for KSBRM group, respectively. The remission induction rate, relapse rate and DFS rate were not different between the two groups.CONCLUSION:
The current study showed that KSBRM regimen was as equivalent as Okayama regimen for remission induction rate, relapse rate and 3-year Kaplan-Meier DFS despite the advantage of shortening of treatment duration by 1 year.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Recurrencia
/
Inducción de Remisión
/
Leucemia Mieloide Aguda
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Supervivencia sin Enfermedad
Tipo de estudio:
Estudio observacional
Límite:
Niño
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Pediatric Hematology-Oncology
Año:
1999
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS